MORRBID is present in humans and dysregulated in patients with hypereosinophilic syndrome representing a potential therapeutic target for inflammatory disorders characterized by short-lived aberrant myeloid cell duration [78]. Here, MIR4435-2HG is linked to hypereosinophilic syndrome.